Methods of improving myocardial performance in fontan patients using udenafil compositions
The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
1. A method of treating an adolescent with single ventricle heart disease for improving the adolescent's exercise capacity or for increasing the likelihood of improving the adolescent's exercise capacity, whose exercise capacity is adversely affected due to a decline in the adolescent's heart function after Fontan palliation, wherein the adolescent is in need of treatment to improve the adolescent's exercise capacity, or to increase the likelihood of improving the adolescent's exercise capacity as determined by maximum oxygen uptake at maximum exercise output (VO 2 measurement), said method comprising:
orally administering to the adolescent in accordance with a treatment regimen an oral dosage form comprising an effective dose of udenafil, or a pharmaceutically acceptable salt thereof, to improve the adolescent's VO 2 measurement or to increase the likelihood of improving the adolescent's VO 2 measurement for improving the adolescent's exercise capacity or for increasing the likelihood of improving the adolescent's exercise capacity,
wherein the adolescent is a human,
wherein the adolescent has undergone Fontan surgery,
wherein the human adolescent is between about 12 years old and under about 18 years old,
wherein the effective dose of udenafil, or a pharmaceutically acceptable salt thereof, is about 87.5 mg, and
wherein the treatment regimen comprises orally administering the oral dosage form to the human adolescent twice daily.
2. The method of claim 1 , wherein the oral dosage form is a tablet.
3. The method of claim 1 , wherein the oral dosage form is a solid or semi-solid oral dosage form selected from a group consisting of a tablet, a capsule, a gel, a pill, a powder and a suspension.
4. A method of treating an adolescent with single ventricle heart disease for improving the adolescent's exercise capacity or for increasing the likelihood of improving the adolescent's exercise capacity, whose exercise capacity is adversely affected due to a decline in the adolescent's heart function after Fontan palliation, wherein the adolescent is in need of treatment to improve the adolescent's exercise capacity, or to increase the likelihood of improving the adolescent's exercise capacity as determined by maximum oxygen uptake at maximum exercise output (VO 2 measurement), said method comprising:
orally administering to the adolescent in accordance with a treatment regimen an oral dosage form comprising an effective dose of udenafil, or a pharmaceutically acceptable salt thereof, to improve the adolescent's VO 2 measurement or to increase the likelihood of improving the adolescent's VO 2 measurement for improving the adolescent's exercise capacity or for increasing the likelihood of improving the adolescent's exercise capacity,
wherein the adolescent is a human,
wherein the adolescent has undergone Fontan surgery,
wherein the human adolescent is between about 12 years old and under about 18 years old, and
wherein the total daily dose of udenafil, or a pharmaceutically acceptable salt thereof, is from about 125 mg to about 175 mg.
5. The method of claim 4 , wherein the oral dosage form is a tablet.
6. The method of claim 4 , wherein the oral dosage form is a solid or semi-solid oral dosage form selected from a group consisting of a tablet, a capsule, a gel, a pill, a powder and a suspension.